(NP (NP (NN Glucocorticoid) (NN receptor) (NNS characteristics)) (PP (IN in) (NP (NP (NNS monocytes)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ corticosteroid-resistant) (JJ bronchial) (NN asthma))))))) (. .))
(S (NP-SBJ-46 (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN corticosteroid) (NN resistance))) (PP (IN in) (NP (JJ bronchial) (NN asthma)))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (NP (-NONE- *-46)) (PP (IN by) (S (NP-SBJ (-NONE- *)) (VP (VBG determining) (NP (NP (DT the) (NN rank) (NN order)) (PP (IN of) (NP (NN potency))) (PP (IN for) (NP (JJ different) (NNS corticosteroids))) (PP (IN in) (S (NP-SBJ (-NONE- *)) (VP (VP (VBG inhibiting) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT a) (ADJP (CD 3) (NN kD)) (NN molecule))) (PP (IN from) (NP (NP (JJ peripheral) (NN blood) (NNS monocytes)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NP (ADJP-COOD (ADJP (ADJP (JJ corticosteroid-sensitive)) (PRN (-LRB- -LRB-) (ADJP (JJ CS)) (-RRB- -RRB-))) (CC and) (ADJP (ADJP (JJ corticosteroid-resistant)) (PRN (-LRB- -LRB-) (ADJP (JJ CR)) (-RRB- -RRB-)))) (JJ asthmatic) (NNS subjects))))))))) (, ,) (SBAR (WHNP-47 (WDT which)) (S (NP-SBJ (-NONE- *T*-47)) (VP (VBZ augments) (NP (NP (NP (NP (NN leukotriene) (NN B4)) (PRN (-LRB- -LRB-) (NP (NN LTB4)) (-RRB- -RRB-))) (NN generation)) (PP (IN by) (NP (NP (NP (JJ human) (NNS neutrophils)) (PRN (-LRB- -LRB-) (NP (NN PMN)) (-RRB- -RRB-))) (VP (VBN stimulated) (NP (-NONE- *)) (PP (IN by) (NP (NN calcium) (NN ionophore)))))))))))))))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-49 (NP (VBG binding) (NNS studies)) (PP (IN with) (NP (-LRB- -LRB-) (NN 3H) (-RRB- -RRB-) (NN dexamethasone)))) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (NP (-NONE- *-49)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB determine) (NP (NP-COOD (NP (NP (DT the) (NN dissociation) (NN constant)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (CC and) (NP (NP (NN receptor) (NNS numbers)) (PRN (-LRB- -LRB-) (NP (NN Ro)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NNS monocytes)) (PP (IN of) (NP (NP (DT these) (CD two) (NNS groups)) (PP (IN of) (NP (NNS subjects)))))))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN concentration)) (PP (IN of) (NP (NP (NN corticosteroid)) (VP (VBG producing) (NP (NP (CD 50) (NN %) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NN IC50)) (-RRB- -RRB-))))))) (VP (VBD was) (NP-PRD-COOD (NP (NP-54 (CD 600) (NN nM)) (PP (-NONE- *ICH*-50))) (, ,) (NP (NP=54 (CD 70) (NN nM)) (NP=51 (-NONE- *ICH*-52))) (, ,) (CC and) (NP (NP=54 (CD 0.5) (NN nM)) (NP=51 (-NONE- *ICH*-53)))) (PP-50 (IN for) (NP-51 (NN hydrocortisone))) (, ,) (NP-52 (NN methylprednisolone)) (, ,) (CC and) (NP-53 (NN dexamethasone)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (NP (NNS monocytes)) (PP (IN from) (NP (JJ CS) (NNS individuals)))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD was) (NP-PRD (NP (ADJP (RB only) (JJ weak)) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN enhancing) (NN activity))))) (PP (IN by) (NP (DT the) (NNS corticosteroids)))) (PP (IN in) (NP (DT the) (ADJP (JJ CR) (JJ asthmatic)) (NNS individuals)))) (. .))
(S (NP-SBJ (DT The) (NN dexamethasone) (NN Kd)) (VP (VP-COOD (VP (VBD was) (NP-PRD-55 (NP (QP (CD 2.45) (CC (- +)) (CD 0.58)) (NN nM)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN mean)) (CC (- +)) (NP (NN SEM))) (, ,) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 6)))) (-RRB- -RRB-))) (PP-56 (IN in) (NP (DT the) (NP (JJ CS)) (NN group)))) (CC and) (VP (NP-PRD=55 (NP (QP (CD 1.6) (CC (- +)) (CD 0.35)) (NN nM)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN mean)) (CC (- +)) (NP (NN SEM))) (, ,) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 6)))) (-RRB- -RRB-))) (PP=56 (IN in) (NP (DT the) (NP (JJ CR)) (NN group)) (PP (IN of) (NP (NNS patients)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (VP (JJ =) (NP-PRD (CD 0.14)))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ (DT The) (NN Ro)) (VP (VP-COOD (VP (PP-58 (IN in) (NP (DT the) (JJ CS) (NN group))) (VBD was) (NP-PRD-59 (QP (CD 3,605) (CC (- +)) (CD 984)) (VBG binding) (NNS sites)) (PP-60 (IN per) (NP (NN nucleus))) (PRN-61 (-LRB- -LRB-) (NP-COOD (NP (NN mean)) (CC (- +)) (NP (NN SEM))) (, ,) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 6)))) (-RRB- -RRB-))) (CC and) (VP (NP-PRD=59 (QP (CD 4,757) (CC (- +)) (CD 692)) (VBG binding) (NNS sites)) (PP=60 (IN per) (NP (NN nucleus))) (PRN=61 (-LRB- -LRB-) (NP-COOD (NP (NN mean)) (CC (- +)) (NP (NN SEM))) (, ,) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 6)))) (-RRB- -RRB-)) (PP=58 (IN in) (NP (DT the) (JJ CR) (NN group))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (VP (JJ =) (NP-PRD (CD 0.23)))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-62 (NP (NN corticosteroid) (NN resistance)) (PP (IN in) (NP (JJ bronchial) (NN asthma)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-62)) (PP (IN by) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (NP (NN corticosteroid) (NN receptor)) (NNS characteristics))))))))))) (. .))
